Clinical Research Directory
Browse clinical research sites, groups, and studies.
Immune Profiles Evolution Under Immunotherapy for Melanoma
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.
Official title: Immune Profiles Evolution in Patients Treated by Immunotherapy for Melanoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2021-01-27
Completion Date
2031-01
Last Updated
2025-04-06
Healthy Volunteers
No
Conditions
Interventions
venous puncture
Venous punctures will be performed: for patients of cohort A and B1: * before the first immune checkpoint inhibitors monoclonal antibodies infusion (baseline); * between week 6 and week 8 (before the immune checkpoint inhibitors monoclonal antibodies infusion); * each 3 months up to 12 months. for patients of cohort B2: * before the radiotherapy; * within the 6 weeks after the end of radiotherapy; * at the 2 following evaluations (every 3 months).
tumoral biopsy
Cutaneous biopsy: superficial skin, or extended skin biopsy, if it is indicated for patient's care.
Locations (1)
Dermato-oncology department, Ambroise Paré hospital, APHP
Boulogne-Billancourt, France